Evidence map›Paper›PMID 41387402›Full record

ArticleNature communications2025

Mass spectrometry-based profiling of single-cell histone post-translational modifications to dissect chromatin heterogeneity.

Ronald Cutler, Laura Corveleyn, Claudia Ctortecka, Francesca LiCausi, Joshua Cantlon, Alvaro Sebastian Vaca Jacome, Dieter Deforce, Jan Vijg, Maarten Dhaenens, Malvina Papanastasiou and 2 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Ketogenic Diet as an Epigenetic Therapy in SETD1B-Related Epilepsy.Annals of clinical and translational neurology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Ronald Cutler *Department of Genetics, Albert Einstein College of Medicine, Bronx, NY, USA. ronald.cutler@einsteinmed.edu.
Laura Corveleyn *ProGenTomics, Laboratory of Pharmaceutical Biotechnology, Department of Pharmaceutics, Ghent University, Ghent, Belgium.
Claudia Ctortecka *Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-6886-8936
Francesca LiCausiDepartment of Cell Biology, Albert Einstein College of Medicine, Bronx, NY, USA.ORCID http://orcid.org/0000-0003-0321-8083
Joshua CantlonSCIENION US Inc, Phoenix, AZ, USA.
Alvaro Sebastian Vaca JacomeBioNTech, Cambridge, MA, USA.
Dieter DeforceProGenTomics, Laboratory of Pharmaceutical Biotechnology, Department of Pharmaceutics, Ghent University, Ghent, Belgium.ORCID http://orcid.org/0000-0002-0635-661X
Jan VijgDepartment of Genetics, Albert Einstein College of Medicine, Bronx, NY, USA.ORCID http://orcid.org/0000-0002-8457-9595
Maarten DhaenensProGenTomics, Laboratory of Pharmaceutical Biotechnology, Department of Pharmaceutics, Ghent University, Ghent, Belgium.ORCID http://orcid.org/0000-0002-9801-3509
Malvina PapanastasiouBroad Institute of MIT and Harvard, Cambridge, MA, USA. malpap@broadinstitute.org.ORCID http://orcid.org/0000-0003-3378-6612
Steven A CarrBroad Institute of MIT and Harvard, Cambridge, MA, USA. scarr@broad.mit.edu.ORCID http://orcid.org/0000-0002-7203-4299
Simone SidoliDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, NY, USA. simone.sidoli@einsteinmed.edu.ORCID http://orcid.org/0000-0001-9073-6641

Funding

WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI Ulrich Steidl · 1985 to 2026
$111.2M
THE IMPACT OF CELLULAR DEFENSE ON THE ROLE OF Ku80 IN GENOME MAINTENANCE AND LONGP01AG017242 · NIA · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · PI VIJG, JAN · 1999 to 2023
$46.1M
The role of hyaluronan in longevity and cancer resistance of longest-lived rodentP01AG047200 · NIA · UNIVERSITY OF ROCHESTER · PI Vadim N. Gladyshev · 2014 to 2026
$36.9M
Validation and characterization of the identified variants associated with human longevity in mouse modelsU19AG056278 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI JAN VIJG · 2017 to 2026
$24.5M
ProteomicsP01CA206978 · NCI · DANA-FARBER CANCER INST · PI WU, CATHERINE JU-YING · 2016 to 2025
$17.0M
Einstein's Nathan Shock Center of Excellence in Basic Biology of AgingP30AG038072 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI VIJG, JAN · 2010 to 2024
$10.8M
Training in Aging ResearchT32AG023475 · NIA · ALBERT EINSTEIN COL OF MED YESHIVA UNIV · PI NIR J BARZILAI, DEREK Major HUFFMAN · 2004 to 2026
$8.6M
Center of Excellence for High Throughput Proteogenomic CharacterizationU24CA270823 · NCI · BROAD INSTITUTE, INC. · PI STEVEN A CARR, MICHAEL A GILLETTE · 2022 to 2026
$5.3M
Proteogenomic Predictors of Recurrence in Non-small Cell Lung CancerU01CA271402 · NCI · WASHINGTON UNIVERSITY · PI STEVEN A CARR, MICHAEL A GILLETTE · 2022 to 2026
$5.0M
Cross-Validation of Genome Integrity Assays in Primary Human CellsU01ES029519 · NIEHS · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI SPIVACK, SIMON D, VIJG, JAN · 2018 to 2022
$3.6M
Integrative, age-related changes in genome and epigenome in human lung in relation to smokingU01HL145560 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI SPIVACK, SIMON D, VIJG, JAN · 2019 to 2022
$2.6M
Genomic Instability-Induced Senescence in Brain Aging and Alzheimer's DiseaseRF1AG068908 · NIA · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI CAMPISI, JUDITH, MONTAGNA, CRISTINA · 2020 to 2020
$1.8M
NCI NIH HHS P01 CA206978NCI NIH HHS P30 CA013330NCI NIH HHS U01 CA271402NCI NIH HHS U24 CA270823NHLBI NIH HHS U01 HL145560NIA NIH HHS P01 AG017242NIA NIH HHS P01 AG047200NIA NIH HHS P30 AG038072NIA NIH HHS RF1 AG068908NIA NIH HHS T32 AG023475NIA NIH HHS U19 AG056278NIEHS NIH HHS U01 ES029519NIH HHS S10 OD030286
6 · The paper itself

Abstract

Single-cell proteomics confidently quantifies cellular heterogeneity, however quantification of post-translational modifications, such as those deposited on histone proteins, remains elusive. Here, we develop a robust mass spectrometry-based method for the unbiased analysis of single-cell histone post-translational modifications (sc-hPTM). sc-hPTM identifies both single- and combinatorial histone post-translational modifications (67 peptidoforms in total), which includes nearly all frequently studied histone post-translational modifications with comparable reproducibility to traditional bulk experiments. As a proof of concept, we treat cells with sodium butyrate, a histone deacetylase inhibitor, and demonstrate that our method can i) distinguish between treated and untreated cells, ii) identify sub-populations of cells with heterogeneous response to the treatment, and iii) reveal differential co-regulation of histone post-translational modifications in the context of drug treatment. The sc-hPTM method enables comprehensive investigation of chromatin heterogeneity at single-cell resolution and provides a further understanding of the histone code.

Indexed as

ChromatinHistonesMass SpectrometryProtein Processing, Post-TranslationalSingle-Cell AnalysisButyric AcidHistone CodeHistone Deacetylase InhibitorsHumansProteomicsButyric AcidChromatinHistone Deacetylase InhibitorsHistones

Identifiers

PMID41387402
PMCPMC12700877

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.